Cancer Biomarkers Market
Description
Global cancer biomarkers market is estimated to be valued at USD 28.90 Bn in 2025 and is expected to exhibit a CAGR of 12.9% during the forecast period (2025-2032).
Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or aBnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient’s cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.
Market Dynamics
Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.
Key Features of the Study
Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or aBnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient’s cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.
Market Dynamics
Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.
Key Features of the Study
- This report provides in-depth analysis of the global cancer biomarkers market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cancer biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes bioMérieux Inc., INOVIQ, Bio-Rad Laboratories Inc., Abbott, Becton Dickinson and Company, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., Siemens Healthineers, F. Hoffmann-la Roche Ltd, Agilent Technologies, Inc, Invitae Corporation, Myriad Genetics, Guardant Health, Illumina, and FOUNDATION MEDICINE, INC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market.
- Biomarker Type Insights (Revenue, USD Bn, 2020 - 2032)
- CA 125
- HER2
- EGFR
- CD20
- BRAF
- Calcitonin
- Others
- Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Kidney Cancer
- Liver Cancer
- Head & neck Cancer
- Non-small Cell Lung Cancer
- Other Cancers
- Profiling Technology Insights (Revenue, USD Bn, 2020 - 2032)
- OMICS Technology
- Imaging Technology
- Immunoassays
- Cytogenetics
- Others
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- bioMérieux Inc.
- INOVIQ
- Bio-Rad Laboratories Inc.
- Abbott
- Becton Dickinson and Company
- Merck KgaA
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- CENTOGENE N.V.
- PerkinElmer Inc.
- Siemens Healthineers
- F. Hoffmann-la Roche Ltd.
- Agilent Technologies, Inc.
- Invitae Corporation
- Myriad Genetics
- Guardant Health
- Illumina
- FOUNDATION MEDICINE, INC.
Table of Contents
156 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Biomarker Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Profiling Technology
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- PEST Analysis
- 4. Global Cancer Biomarkers Market, By Biomarker Type, 2020 – 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- CA 125
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- HER2
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- EGFR
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- CD20
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- BRAF
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Calcitonin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- 5. Global Cancer Biomarkers Market, By Cancer Type, 2020 – 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Kidney Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Liver Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Head & neck Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Non-small Cell Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Other Cancers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- 6. Global Cancer Biomarkers Market, By End User, 2020 – 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- OMICS Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Imaging Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Immunoassays
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Cytogenetics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- 7. Global Cancer Biomarkers Market, By End User, 2020 – 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Diagnostic Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
- 8. Global Cancer Biomarkers Market, By Region, 2020 – 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021–2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 – 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- bioMérieux, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- INOVIQ
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bio-Rad Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Becton, Dickinson and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CENTOGENE N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PerkinElmer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-la Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Myriad Genetics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Illumina
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- FOUNDATION MEDICINE, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- 10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
